You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company also anticipates at least one of its drugs will move into phase III testing by the end of 2010, a milestone that could put it in a position to make a second attempt at going public.
Wayne State will use a $6.3 million NIH grant to study Charcot-Marie-Tooth genetics and pursue treatments.
The drug's initial indication will be non-arteritic anterior ischemic optic neuropathy, a rare condition that can lead to permanent blindness, but the company expects to ultimately develop it as glaucoma therapy.
The molecular diagnostics developer will use the GeneCards genomic database in neurological disease biomarker research.
A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.
Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.
The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.
In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.